Huberman LabHow Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks
At a glance
WHAT IT’S REALLY ABOUT
Psilocybin’s Power: Targeted Neuroplasticity, Profound Journeys, And Real Risks
- Andrew Huberman explains how psilocybin, a serotonin‑like tryptamine, selectively activates the 5‑HT2A receptor to expand brain connectivity and drive neuroplasticity. He details how this underlies acute psychedelic effects—hallucinations, ego dissolution, synesthesia—and the longer‑term rewiring that can improve mood, addiction, and compulsive disorders. The episode emphasizes that outcomes depend heavily on dose, set and setting, music, eyes‑closed protocols, and skilled guides, and that psilocybin remains illegal (Schedule I) with serious contraindications for youth and anyone prone to psychosis. Huberman reviews human and animal data showing structural and functional brain changes, highlights clinical trials where one or two high‑dose sessions outperform SSRIs for treatment‑resistant depression, and stresses that plasticity is only beneficial if it leads to adaptive, not maladaptive, behavioral change.
IDEAS WORTH REMEMBERING
5 ideasPsilocybin works mainly by strongly activating the serotonin 2A (5‑HT2A) receptor, not by globally boosting serotonin.
Although psilocybin/psilocin are structurally similar to serotonin, psilocybin is unusually selective for the 5‑HT2A receptor, which is densely expressed in neocortical regions like prefrontal and visual cortex. This receptor selectivity explains why psilocybin produces focused effects—hallucinations, altered cognition, and powerful plasticity—versus the broad, often side‑effect‑heavy modulation produced by SSRIs that generally increase serotonin at many receptor subtypes.
Adaptive outcomes depend on set, setting, and eyes‑closed, music‑guided sessions—not just taking the drug.
Clinical trials consistently use controlled indoor settings with one or two sober, trained guides, safety measures (no access to streets, windows, water), and an eye mask for most of the journey. Carefully curated music ramps from low‑intensity to percussive, emotionally intense tracks at the peak, then softer, nature‑like sounds as the journey tapers. This structure shifts attention away from external visual distortions toward internal emotions, memories, and insights, biasing plasticity toward therapeutic, not chaotic, rewiring.
Clinically effective doses are relatively high and sharply distinct from typical “microdoses.”
Microdosing in research is typically 1–3 mg psilocybin per day, whereas therapeutic macrodoses for depression are 25–30 mg per session, usually administered once or twice. Roughly, 1 g of dried mushrooms (~1% psilocybin) ≈ 10 mg psilocybin, but real mushroom content varies from 0.5–2%, so a 'gram' could mean 5–20 mg. Clinical trials show 25 mg produces robust antidepressant effects; 10 mg often performs no better than very low‑dose control, underlining that sub‑perceptual doses are not what’s driving the strong outcomes in current depression trials.
Psilocybin expands functional brain connectivity and induces concrete structural changes like new dendritic spines.
Imaging in humans shows reduced modularity and hierarchy—more cross‑talk between sensory, emotional, and higher‑order networks during and after sessions. Animal studies (e.g., Neuron paper on frontal cortex) reveal rapid, persistent growth of dendritic branches and mushroom‑shaped spines on pyramidal neurons after psilocybin, providing new synaptic sites. These changes likely underpin longer‑term shifts in mood, perception, and behavior, though doses in rodent work are often higher (per kg) than in human clinical practice.
The quality of the acute experience—especially ‘oceanic boundlessness’—predicts antidepressant response better than hallucinations per se.
In treatment‑resistant depression trials, higher ratings of unity, spirituality, bliss, and insight (often called 'oceanic boundlessness') correlate strongly with positive long‑term mood outcomes. Merely seeing complex imagery or having synesthesia does not predict benefit. Interestingly, while some anxiety and ego dissolution at the peak seem important to 'letting go,' very high subjective anxiety is negatively associated with therapeutic response, reinforcing the need for dosing, support, and in‑session tools (like controlled breathing) to keep arousal within a tolerable range.
WORDS WORTH SAVING
5 quotesJust because something invokes neuroplasticity, changes in brain circuitry, does not mean that it's therapeutic.
— Andrew Huberman
Psilocybin mainly binds to and activates the so-called serotonin 2A receptor... that's really the one responsible for triggering all the changes in neural circuitry.
— Andrew Huberman
It is very clear that having an eye mask... for the majority, if not the entire psilocybin session is going to be very useful.
— Andrew Huberman
You should think of psilocybin and other psychedelics as initiating the neuroplasticity process, but they are not the neuroplasticity process itself.
— Andrew Huberman
The effect sizes reported in this study were approximately 2.5 times greater than psychotherapy, and more than four times greater than psychopharmacologic depression treatment studies.
— Andrew Huberman (summarizing clinical trial findings)
High quality AI-generated summary created from speaker-labeled transcript.
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome